Dr. Daniel Von Hoff
Dr. Daniel Von Hoff has dedicated his medical life towards discovering a cure of cancer. Especially subduing pancreatic cancer. Marching towards the ultimate achievement, Dr. Von Hoff works tirelessly to create drugs and treatments that extend quality of life. In spite of spending long exhausting days in clinical research, Dr. Von never loses compassionate sight of his patients and their loved ones. He specializes in the toughest of cancer cases where conventional treatments have failed and patients have little hope of surviving.
Many of his colleagues consider Dr. Von Hoff one of the world’s foremost oncologist, medical researcher and cancer scientist. Renowned for his pancreatic cancer research and involvement in the development of more than a half-dozen revolutionary drugs that have extended the lives of countless pancreatic patients. He has led or been an instrumental participant on more than 200 clinical trials during his career.
Does Dr. Von Hoff Ever Sleep?
The American Society of Clinical Oncology has honored Dr. Von Hoff with its most prestigious award in the field of cancer research. He was recently (2014) honored by Hope Funds for Cancer Research with its Award of Excellence in recognition of outstanding achievement in the fields of research, drug development, medicine, patient support and philanthropy. Dr. Daniel Von Hoff has won so many distinguished awards and recognized for so many accomplishments as well as empathy and personal care that he can be described as a “physician on steroids”.
Dr. Daniel Von Hoff is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program, Executive Vice President, Translational Genomics Research Institute (TGen), Director, TGen’s Translational Drug Development Division and Head, Pancreatic Cancer Research Program. He is also Chief Scientific Officer for US Oncology.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
Laboratory contributions have been in the area of in-vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004 – March 2010.
Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.